864 results on '"Wick W."'
Search Results
2. Can Schrodingerist Wavefunction Physics Explain Brownian Motion? II. The Diffusion Coefficient
3. Can Schroedingerist Wavefunction Physics Explain Brownian Motion?
4. Patient, Relative and Staff Experiences of Clinical Trial Participation in Neurooncology: “Maybe You Can Also Show the Positive, No Matter How It Ends&rdquo
5. On Schr\'odingerist Quantum Thermodynamics
6. On Non-Linear Quantum Mechanics, Space-Time Wavefunctions, and Compatibility with General Relativity
7. Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
8. On Non-Linear Quantum Mechanics and the Measurement Problem IV. Experimental Tests
9. On Non-Linear Quantum Mechanics and the Measurement Problem III. Poincare Probability and ... Chaos?
10. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
11. On Non-Linear Quantum Mechanics and the Measurement Problem II. The Random Part of the Wavefunction
12. On Non-linear Quantum Mechanics and the Measurement Problem I. Blocking Cats
13. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
14. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors
15. Emerging targets for anticancer vaccination: IDH
16. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up
17. Stopping the SuperSpreader Epidemic, Part III: Prediction
18. Stopping the SuperSpreader Epidemic, Part II: MERS Goes Pandemic
19. Stopping the SuperSpreader Epidemic: the lessons from SARS (with, perhaps, applications to MERS)
20. Biologically-directed modeling reflects cytolytic clearance of SIV-infected cells in vivo in macaques.
21. NLGN4X TCR transgenic T cells to treat gliomas
22. PL01.4.A LATE BREAKING ABSTRACT: A LONG PEPTIDE VACCINE TARGETING THE CLONAL DRIVER MUTATION H3K27M IN ADULT PATIENTS WITH DIFFUSE MIDLINE GLIOMA
23. KS01.5.A LATE BREAKING ABSTRACT: LONG-TERM FOLLOW-UP OF PATIENTS WITH NEWLY DIAGNOSED IDH-MUTANT ASTROCYTOMA AFTER IDH1-VAC TREATMENT
24. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours
25. Neurocognitive impairment and patient-proxy agreement on health-related quality of life evaluations in recurrent high-grade glioma patients
26. DEGRO practical guideline for central nervous system radiation necrosis part 1: classification and a multistep approach for diagnosis
27. DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development
28. Leptomeningeal metastasis from solid tumours:EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
29. Primäre intrakranielle und spinale Tumoren
30. Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
31. Factors associated with health-related quality of life (HRQoL) deterioration in glioma patients during the progression-free survival period
32. 185P Interim analysis of the EOGBM1-18 study: Strong immune response to therapeutic vaccination with EO2401 microbiome derived therapeutic vaccine + nivolumab
33. 170P EO2401 microbiome derived therapeutic vaccine + nivolumab +/- bevacizumab, in neoadjuvant, adjuvant and non-surgery linked treatment of recurrent glioblastoma: Phase I-II EOGBM1-18/ROSALIE study
34. PL02.1.A EO2401, a novel microbiome-derived therapeutic vaccine for patients with recurrent glioblastoma: ROSALIE study
35. P11.48.A Primary CNS lymphoma after CLIPPERS: a case series
36. JS08.6.A A connectivity signature for glioblastoma
37. OS08.2.A Three layers of neuronal-like mechanisms driving brain tumor invasion
38. KS05.6.A Oral DNA vaccination targeting VEGFR2 combined with the anti-PD-L1 antibody avelumab in patients with progressive glioblastoma - final results. NCT03750071
39. 303P EO2401 (EO) therapeutic vaccine for patients (pts) with recurrent glioblastoma (GB): Phase I/II ROSALIE study
40. OS07.5.A Report from the pooled analysis of the randomized trials NORDIC, NOA-8 and CE.6 on elderly patients with glioblastoma
41. P12.12.A Resolving the cellular architecture of infiltration zones in glioblastoma
42. Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated
43. Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma
44. Diffusion in a Singular Random Environment
45. Asymptotic Equivalence of Fluctuation Fields for Reversible Exclusion Processes with Speed Change
46. Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment
47. P13.01 Neuronal activity drives distinct invasion modes of glioma cells
48. Estimation of Wear and Lifetime for an Improved Turbine Operation
49. P07.04 Rapid-CNS2: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study
50. KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.